Blog Layout
Gestalt Diagnostics Expands Market Reach and Solution Offerings with Peak Medical Acquisition
Gestalt Diagnostics announced today that it has finalized the acquisition of laboratory integration services company Peak Medical. This strategic acquisition expands Gestalt’s digital pathology integration services division and provides key industry expertise in healthcare connectivity services in addition to integration and support for LIS solutions.
Peak, and its employees, will be fully integrated into Gestalt and will become a key solution and
service offering to both company’s customers. The two companies will be combined under the Gestalt
Diagnostics name and brand. Peak customers will be seamlessly integrated into the family of Gestalt
customers.
“Our companies share a common goal of providing top ranking solutions and services to the hospital
and laboratory community.” says Dan Roark, Chief Executive Officer, Gestalt Diagnostics. “The
acquisition of Peak will expand Gestalt’s expert team to include skills and experience for all types of
connectivity with direct expertise in supporting legacy and current LIS’s alike. Peak has long standing
relationships with many of the leading pathology laboratories in the United States which speaks
volumes to their team’s abilities. We are excited to add Peak’s customers to our customer base and
are happy to be able to offer them the same level of service they have always enjoyed combined with
new solutions and the ability to include digital pathology to their roadmap under one umbrella. The
addition of Ethan and his team will ensure that the relationships that Peak’s customers have enjoyed
will continue.”
Ethan Lynn, President, Peak Medical says, “Gestalt’s vision is the future of pathology informatics and
all of us on the Peak team are excited to be a part of it. Peak has prided itself on providing the very
best service and affordable solutions for our customers and Gestalt is a great fit. The breadth of
Gestalt’s products and talent base will allow us to offer our customers a broader depth of service and
software options than we ever have before. With profit margins tightening for the pathology business
every year, a digital pathology workflow is becoming essential for labs to survive. Peak is honored to
be a part of the digital pathology movement and we look forward to servicing our clients even better
through Gestalt.”
About Gestalt Diagnostics
Gestalt Diagnostics is a private, profit-driven software company who has developed PathFlow, an
enterprise software platform specifically designed to bring the benefits of digital workflow to
pathologists and pathology laboratories. This product was originally developed, by what is now
Gestalt’s team, to support a fully digital reading platform for radiology. The radiology platform
is used in leading hospitals across the United States and supports more than 15 million
studies annually. Gestalt has expanded and redesigned this proven, robust solution to work in
the laboratory space – engineered for the unique needs and workflow of pathologists.
About Peak Medical
Peak Medical Technologies is the nationwide leader in Pathology software solutions and IT support.
We provide excellence in service and a commitment to creating and maintaining the best pathology
laboratory practices possible. Peak Medical Technologies is setting the standard in lean-laboratory
workflow, efficiency and accuracy. The technology required to maintain relevance and a competitive
advantage within the Pathology laboratory infrastructure is constantly evolving. It is clear that new
and improved technologies have the ability to change workflow practices for the better. We strive to
take your IT processes to the next level and make your pathology business more profitable.
Gestalt’s Advisory Board guides the development of Gestalt’s digital pathology platform,
PathFlow® – made by pathologists for pathologists
A Digital Pathology Today podcast with Lisa-Jean Clifford of Gestalt - A Fresh Start for Pathology
Gestalt Diagnostics, Inc., a leading provider of (AI)-driven digital pathology solutions, is proud to announce the launch of its leading-edge AI Algorithm Evaluator. This groundbreaking, patent-pending tool empowers pathologists, researchers, and healthcare professionals to assess and compare the performance of AI algorithms with unprecedented precision directly within our award-winning PathFlow® solution. This new feature will be demonstrated during the USCAP 2024 conference in Baltimore this week.
March 20, 2024 – Spokane, Washington – Gestalt, a leading provider of (AI)-driven digital pathology solutions, is excited to announce a series of significant enhancements to its educational module and digital pathology solution, within the PathFlow® solution. These advancements underscore Gestalt's commitment to transforming healthcare from every perspective. Our newly expanded Education Module now includes automated, digital evaluation, proficiency testing, credentialing management, and results comparison features. Designed to streamline and ease the heavily manual processes of pathologist proficiency testing, onboarding, and credentialing. "Our commitment to innovation extends across all facets of pathology, from Anatomic Pathology (AP), Research, and Education to Management and Administrative functions. These enhancements reflect our vision for a future where education and technology converge to improve operational processes," says Lisa-Jean Clifford, Chief Strategy Officer and COO at Gestalt Diagnostics. "Our solutions are designed to significantly streamline workflow, enhance efficiency, support patient safety, and offer improved quality and cost. We believe that delivering products with these goals in mind will have a major impact on operations within healthcare, academic, and research facilities, for the pathologist, scientist, and clinician, ultimately providing faster, more accurate diagnosis and treatment for the patient and optimized operations with significant savings to organizations." Gestalt Diagnostics has a proven track record of excellence. Its customers are already leveraging the company's expertise for primary diagnoses*, tumor boards, onboarding and training, collaboration, and supporting remote access for hundreds of client pathologists who are geographically dispersed. Additionally, Gestalt supports research and retrospective image and data capture for over 10 million pathology slides. Join us at USCAP, March 23-28, at booth #554 to see how our efforts in clinical, education, and research initiatives are setting new standards in digital solutions. *Research use only unless following CAP guidelines for LDT. CE-IVD certified for use in Europe.
Featured in G2 Intelligence January 2024—In an insightful discussion on the evolving landscape of data analytics within clinical laboratories, Lisa-Jean Clifford, COO and Chief Strategy Officer at Gestalt Diagnostics, highlights the integration of data analytics across various facets of laboratory operations. She emphasizes its critical role in enhancing operational efficiency, resource management, and patient safety. Clifford's commentary sheds light on the extensive applications of data analytics in lab environments—from streamlining operational workflows to improving patient care. She also addresses the challenges labs face, such as navigating the vast array of data analytics solutions and the need for specialized knowledge in pathology informatics. Moreover, Clifford points to the promising future of digital solutions and AI in expanding the capabilities of clinical labs, suggesting a burgeoning potential for growth and innovation in the field.
January 11, 2024 – Spokane, Washington – Gestalt announces the addition of Sagis Diagnostics to their customer roster. Recognizing the evolving landscape of healthcare technology, Sagis has embraced a transformative approach to their pathology services and has added digital pathology to their strategy. Gestalt’s industry leading, award-winning platform will be implemented for use in clinical and academic workflows, to include integrated artificial intelligence algorithms. By leveraging cutting-edge technology, Sagis aims to streamline the diagnostic process and enhance overall efficiency. The advantages of transitioning to digital pathology for the company include reducing operational costs and delays related to courier services and enabling real-time collaboration and access to patient cases for pathologists in various locations. “We believe that digital pathology is not just a technological upgrade but a strategic move towards a more sustainable and efficient future. By partnering with Gestalt, we aim to provide our pathologists with a state-of-the-art platform that aligns with our commitment to excellence," said Lynn Brock, COO at Sagis. “The thorough evaluation of various vendors led us to select Gestalt as the preferred partner. Through an exhaustive comparison of features, applications, and a detailed matrix analysis, Gestalt emerged as the vendor that best met our requirements, ticking off all the crucial aspects in clinical, research, and educational domains. This decision aligns with our commitment to staying at the forefront of technological advancements in healthcare.” The decision to embrace digital pathology was driven by several key factors. Initially, Sagis recognized significant cost-saving potential by eliminating the need for daily courier services to multiple cities in Texas, while also addressing challenges posed by weather conditions and unforeseen disruptions. Furthermore, Sagis sought to leverage Artificial Intelligence (AI) capabilities to empower pathologists and optimize diagnostic processes. The integration of AI allows for the pre-screening of specimens before pathologists begin their workday, ensuring a prioritized and efficient diagnostic workflow. A crucial aspect of this shift is the ability to attract and retain pathologists in an ever-shrinking pool of talent. The flexibility offered by digital pathology allows pathologists to work remotely, eliminating the need for relocation. This not only addresses the current challenges in hiring pathologists but also positions Sagis as an innovative and attractive employer in the healthcare sector. Gestalt COO & Chief Strategy Officer, Lisa-Jean Clifford says, “This shift represents a significant milestone in Sagis's commitment to delivering high-quality pathology services while embracing the opportunities presented by digital innovation. We are proud to work with innovative laboratories like Sagis who have a broad vision for expansion and use of technology and the positive impact this transition will have on patient care, as well as the broader healthcare ecosystem.” About Sagis Sagis is an entirely physician-led pathology group backed by a CLIA and CAP-accredited histology lab located in the heart of Houston, Texas. With board-certified and subspecialty-trained pathologists always within reach, we deliver the highest quality services to physicians, physician groups, ambulatory surgery centers, and hospitals. Our commitment to quality and excellence is built upon our expertise and the utilization of the latest diagnostic tools. Providing accurate, prompt, and clear diagnoses in a personal and customizable manner, we prioritize our referring physicians' needs. As a patient-centric facility, we strive to deliver the best medical care possible. Visit Sagis at www.sagisdx.com *Research use only unless following CAP guidelines for LDT. CE-IVD certified for use in Europe.
This award is another validation of Gestalt's contributions to supporting better healthcare through technology.
Featured in CAP TODAY December 2023—Digital pathology and AI—the push, the potential, the changing questions, the reimbursement, and the caution. All that and more came up when CAP TODAY publisher Bob McGonnagle led a conversation online with pathologists and industry representatives, featuring Lisa-Jean Clifford, COO and Chief Strategy Officer of Gestalt.
With the advancement and expanded uses of technology in the laboratory we have a host of opportunities in the hands of physicians and scientists to explore and study diseases in-depth and in a way that we historically have not been able to. Read on to discover more...
